Objective: The Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) is a key measure of social cognition in schizophrenia that has good psychometric properties and is recommended by the MATRICS committee. As a way to further investigate the validity of the MSCEIT, this study sought to examine the neurobiological correlates of MSCEIT performance in patients with early course schizophrenia. Methods: A total of 51 patients diagnosed with early course, stabilized schizophrenia or schizoaffective disorder completed structural magnetic resonance imaging (MRI) scans and the MSCEIT. Investigation of the associations between MSCEIT performance and gray matter morphology was examined by conducting voxel-based morphometry (VBM) analyses across hypothesized social-cognitive regions of interest using automated anatomical labeling in Statistical Parametric Mapping Software, version 5 (SPM5). All VBM analyses utilized general linear models examining gray matter density partitioned images, adjusting for demographic and illness-related confounds. VBM results were then followed up with confirmatory volumetric analyses. Results: Patients with poorer overall and Facilitating, Understanding, and Managing Emotions subscale performances on the MSCEIT showed significantly reduced gray matter density in the left parahippocampal gyrus. Additionally, attenuated performance on the Facilitating and Managing Emotions subscales was significantly associated with reduced right posterior cingulate gray matter density. All associations observed between MSCEIT performance and gray matter density were supported with confirmatory gray matter volumetric analyses, with the exception of the association between the right posterior cingulate and the facilitation of emotions. Conclusion: These findings provide additional evidence for the MSCEIT as a valid social-cognitive measure by elucidating its correlates with neurobiological structures commonly implicated in emotion processing. These findings provide additional biological evidence supporting the use of the MSCEIT in cognitive enhancing clinical trials in schizophrenia.
Introduction
Cognitive impairment in schizophrenia is now considered a central characteristic of the disorder (Heinrichs and Zakzanis, 1998; Keefe and Fenton, 2007) , with recent evidence recognizing the particularly important contribution of social-cognitive impairments on functional outcomes (Couture et al., 2006; Green and Horan, 2010; Vauth et al., 2004) . Despite recognition of the centrality of social-cognitive deficits in schizophrenia, the availability of tools for the assessment of social cognition in the disorder has been limited (Green et al., 2004) . The Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT; Mayer et al., 2003) has emerged as a promising measure of social cognition in schizophrenia. Indeed, the National Institute of Mental Health's (NIMH) committee on Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) has recommended that the MSCEIT be the key measure for assessing social-cognitive outcomes in clinical trials of cognitive enhancers in schizophrenia (Green et al., 2005) . Additionally, previous investigations of the MSCEIT have demonstrated strong psychometric properties for assessing the emotional components of social cognition in the disorder (Eack et al., 2010; Kee et al., 2009; Nuechterlein et al., 2008) , and has also documented the sensitivity of the MSCEIT for detecting social-cognitive treatment effects (Eack et al., 2007) , underscoring its potential utility for use in clinical trials.
A critical component to the continued validation of the MSCEIT is the identification of the neural underpinnings that subserve performance Progress in Neuro-Psychopharmacology & Biological Psychiatry 40 (2013) 207-212 
